

**TEXAS MEDICAID
Clinical Edit Prior Authorization
Growth Hormones:
GENOTROPIN & NORDITROPIN**

Texas Children's Health Plan Only

STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING


Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:
Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:

STEP 2: INDICATE PREFERRED PHARMACY


- Texas Children's Specialty Pharmacy (for Texas Children's providers only) (Phone: 832-824-6337, Fax: 832-825-0627)
- Maxor Pharmacy (Phone: 866-629-6779, Fax: 866-217-8034)
- Premier Kids Care Pharmacy (Phone: 888-892-9001, Fax: 866-810-4021)
- CVS/Pharmacy #2751 – Fort Worth, TX (Phone: 866-566-1548, Fax: 866-320-8853)
- CVS/Pharmacy #2859 – San Antonio, TX (Phone: 210-616-0080, Fax: 210-614-7859)
- CVS/Pharmacy #2921 – Monroeville, PA (Phone: 800-238-7828, Fax: 877-287-7226)
- InTouch Pharmacy (Phone: 877-874-5099, Fax: 706-534-6722)
- Goodsense Pharmacy (Phone: 210-802-2640; Fax: 210-802-2680)

STEP 3: CLINICAL PRIOR AUTHORIZATION CRITERIA

Indicate Primary Diagnosis: _____ ICD-10 Code: _____



<p>1. Is the client 0 to 16 (greater than (>) 0 and less than or equal to (\leq) 16) years of age?</p> <p><input type="checkbox"/> Yes (Go to # 2) <input type="checkbox"/> No (Go to # 9)</p>
<p>2. Does the client have a diagnosis of growth hormone deficiency (GHD) or idiopathic short stature (ISS) in the last 3 years?</p> <p><input type="checkbox"/> Yes (Go to # 8) <input type="checkbox"/> No (Go to # 3)</p>
<p>3. Does the client have a diagnosis of panhypopituitarism in the last 3 years?</p> <p><input type="checkbox"/> Yes (Go to # 4) <input type="checkbox"/> No (Go to # 5)</p>
<p>4. Has the client had at least 2 claims for the requested medication in the last 90 days (stable therapy)?</p> <p><input type="checkbox"/> Yes (Go to # 13) <input type="checkbox"/> No (Go to # 8)</p>
<p>5. Does the client have a diagnosis of ONE (1) of the following in the last 3 years?</p> <ul style="list-style-type: none">• Short Stature Homeobox-Containing Gene (SHOX) Deficiency• Turner Syndrome• Noonan Syndrome• Prader-Willi Syndrome <p><input type="checkbox"/> Yes (Go to # 13) <input type="checkbox"/> No (Go to # 6)</p>
<p>6. Does the client have a diagnosis of chronic kidney disease (CKD) in the last 3 years?</p> <p><input type="checkbox"/> Yes (Go to # 7) <input type="checkbox"/> No (Deny)</p>
<p>7. Does the client have a history of a renal transplant (CPT) in the last 3 years?</p> <p><input type="checkbox"/> Yes (Deny) <input type="checkbox"/> No (Go to #8)</p>
<p>8. Does the submitted documentation support the requested diagnosis? [Manual Step - NOTE: For initial requests, documentation must be from within the past 12 months. For renewal requests, documentation must be from within the past 6 months].</p> <p><input type="checkbox"/> Yes (Go to # 13) <input type="checkbox"/> No (Deny)</p>
<p>9. Does the client have a diagnosis of panhypopituitarism in the last 3 years?</p> <p><input type="checkbox"/> Yes (Go to # 11) <input type="checkbox"/> No (Go to # 10)</p>



10. Does the client have a diagnosis of growth hormone deficiency (GHD) or idiopathic short stature (ISS) in the last 3 years?

Yes (Go to # 12)

No (Deny)

11. Has the client had at least 2 claims for the requested medication in the last 90 days (stable therapy)?

Yes (Go to # 13)

No (Go to # 12)

12. Does the submitted documentation support the requested diagnosis? [Manual Step - NOTE: For initial requests, documentation must be from within the past 12 months. For renewal requests, documentation must be from within the past 6 months].

Yes (Go to # 13)

No (Deny)

13. Does the client have a diagnosis of active malignancy in the last 180 days?

Yes (Deny)

No (Go to # 14)

14. Does the client have a history of chemotherapy/radiation (CPTs) in the last 180 days?

Yes (Deny)

No (Go to # 15)

15. Does the client have a diagnosis of active proliferative or severe non-proliferative diabetic retinopathy in the last 365 days?


Yes (Deny)

No (Approve – 365 days)

STEP 4: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553

Prescriber Signature: _____ **Date:** _____


If criteria not met, submit chart documentation with form citing complex medical circumstances.
For questions, please call Navitus Customer Care at 1-877-908-6023.




GROWTH HORMONE QUICK REFERENCE GUIDE

Testing Requirements for Clients ≤ 16 Years of Age

Growth Hormone (Excluding Serostim and Zorbtive) Growth Hormone Deficiency, Idiopathic Short Stature, Panhypopituitarism, Chronic Kidney Disease, SHOX Deficiency, Turner Syndrome, Noonan Syndrome and Prader-Willi Syndrome in Children	
Diagnosis	Testing Requirements: For initial requests, documentation must be from within the past 12 months. For renewal requests, documentation must be from within the past 6 months
Panhypopituitarism	<p><u>Initiation of GH Therapy:</u></p> <ul style="list-style-type: none"> • IGF-1 level < 160 ng/mL, AND • Failure to respond (response ≤ 5 ng/mL) to one growth hormone stimulation test (Note: children < 12 months of age are excluded from provocative testing) <p><u>Renewal of GH Therapy:</u></p> <ul style="list-style-type: none"> • No additional testing is required
Growth Hormone Deficiency (GHD)	<p><u>Initiation of GH Therapy:</u></p> <ul style="list-style-type: none"> • Failure to respond (response < 10 ng/mL) to at least 2 growth hormone stimulation tests (Note: children < 12 months of age are excluded from provocative testing), AND • Patient's height > 2.25 SD below the mean for age OR patient's height > 2 SD below the midparental height percentile, AND • Growth velocity < 25th percentile for bone age <p><u>Renewal of GH Therapy:</u></p> <ul style="list-style-type: none"> • Patient's growth should exceed 2 cm/year, AND • Epiphyses are open
Idiopathic Short Stature (ISS)	<p><u>Initiation of GH Therapy:</u></p> <ul style="list-style-type: none"> • Height > 2.25 SD below the mean for age, AND • Predicted adult height < 63 inches for males and < 59 inches for females <p><u>Renewal of GH Therapy:</u></p> <ul style="list-style-type: none"> • Patient's growth should exceed 2 cm/year, OR show an increase in height velocity of 50%, OR an increase of at least 2.5 cm/year above the baseline height velocity, AND • Epiphyses are open



<p>Chronic Kidney Disease</p>	<p><u>Initiation of GH Therapy:</u></p> <ul style="list-style-type: none"> • GFR \leq 75mL/min/1.73m², AND • Patient's height > 2.25 SD below the mean for age OR patient's height > 2 SD below the midparental height percentile OR patient's Z score < -1.88, AND • Pre-transplant <p><u>Renewal of GH Therapy:</u></p> <ul style="list-style-type: none"> • Patient's growth should exceed 2 cm/year, AND • Pre-transplant, AND • Epiphyses are open
<p>SHOX Deficiency, Turner Syndrome, Noonan Syndrome and Prader-Willi Syndrome</p>	<ul style="list-style-type: none"> • Diagnosis only is required, no additional testing is requested



Testing Requirements for Clients > 16 Years of Age

Growth Hormone (Excluding Serostim and Zorbtive) Panhypopituitarism, Growth Hormone Deficiency or Idiopathic Short Stature in patients > 16 years of age	
Diagnosis	Testing Requirements: For initial requests, documentation must be from within the past 12 months. For renewal requests, documentation must be from within the past 6 months
Panhypopituitarism	<u>Initiation of GH Therapy:</u> <ul style="list-style-type: none"> IGF-1 level < 160 ng/mL, AND Failure to respond to one growth hormone stimulation test (response \leq 5ng/mL) <u>Renewal of GH Therapy:</u> <ul style="list-style-type: none"> No additional testing is required
Idiopathic Short Stature (ISS)	<u>Renewal of GH Therapy:</u> <ul style="list-style-type: none"> If patient has been treated as a pediatric patient (\leq 16 years of age) and is requesting a refill, patient's growth should exceed 2 cm/year, AND Bone age < 16 years, AND Epiphyses are open
Growth Hormone Deficiency (GHD) with no other pituitary deficiency	<u>Initiation of GH Therapy:</u> <ul style="list-style-type: none"> IGF-1 level < 160 ng/mL, AND Failure to respond to two growth hormone stimulation tests (response \leq 5ng/mL) <u>Renewal of GH Therapy:</u> <ul style="list-style-type: none"> No additional testing is required